Thomsen Pharma ApS: Financial statements 2024
CVR: 40620060
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Thomsen Pharma ApS (CVR 40620060) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -15,092 and a net result of DKK -4,005,382 compared with DKK -5,896 the year before. Equity in the 2024 report amounted to DKK 624,028. The solvency ratio was 97.8%.
- Gross Profit
- DKK -15,092
- Profit/Loss
- DKK -4,005,382
- Equity
- DKK 624,028
- Total Assets
- DKK 637,892
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -15K | -4M | 624K | - |
| 2023 | - | -6K | -6K | 4.6M | - |
| 2022 | - | -27K | -540K | 4.6M | - |
| 2021 | - | -19K | 484K | 5.2M | - |
| 2020 | - | -29K | 1.5M | 4.7M | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
Thomsen Pharma ApS has published its annual report for 2023. Gross profit came to DKK -5,738, and the net result was DKK -5,896.
About Thomsen Pharma ApS
Thomsen Pharma ApS is a Danish company of the type Anpartsselskab based in Glamsbjerg, founded in 2019. The company is registered under the industry Ikke-finansielle holdingselskaber. The management consists of Mikael Søndergaard Thomsen. The company is owned by Mikael Søndergaard Thomsen. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -14,978 and a net result of DKK -16,315 compared with DKK -4,005,382 the year before. Equity in the 2025 report amounted to DKK 607,713.